GlobeNewswire by notified

Kvika banki hf.: Transaction in relation to a share buyback programme


In week 36 Kvika banki hf. („Kvika“ or „the bank“) purchased 4,500,000 of its own shares at the purchase price 74,315,000 ISK. See further details below:

DateTimeNo. of shares purchasedShare price (rate)Purchase price
4.9.2023 10:28:56 250,000  16.850 4,212,500
4.9.2023 11:49:55 250,000  16.850 4,212,500
4.9.2023 13:42:55 250,000  16.850 4,212,500
4.9.2023 15:08:18 250,000  16.800 4,200,000
5.9.2023 11:06:13 250,000  16.600 4,150,000
5.9.2023 13:47:42 500,000  16.650 8,325,000
5.9.2023 15:28:16 250,000  16.400 4,100,000
6.9.2023 14:14:55 200,000  16.400 3,280,000
6.9.2023 15:06:11 500,000  16.425 8,212,500
7.9.2023 11:11:24 300,000  16.325 4,897,500
7.9.2023 13:54:54 500,000  16.325 8,162,500
8.9.2023 11:24:15 500,000  16.350 8,175,000
8.9.2023 14:15:02 250,000  16.350 4,087,500
8.9.2023 15:13:15 250,000  16.350 4,087,500

The trade is in accordance with Kvika‘s buyback programme, announced on 23 June 2023 and based on the authorisation of a shareholders‘ meeting of Kvika held on 30 March 2023.

Kvika held 45,950,000 own shares prior to the notified transacton and has, thus, purchased a total of 50,450,000 shares under the buyback programme, which corresponds to 1.055% of issued shares in the company. Total purchase price is 864,984,500 ISK. Buyback under the programme will amount to a maximum purchase price of 1,000,000,000 ISK.

The buyback programme is in effect from 23 June 2023 until Kvika‘s annual general meeting 2024, unless the maximum purchase price will be reached before that time.

The execution of the buy-back programme must comply with Act on Public Limited Companies, No. 2/1995. In addition, the buy-back programme must be implemented as provided for in the Regulation of the European Parliament and of the Council no. 596/2014, on market abuse, as well as the Commission Delegated Regulation (EU) 2016/1052 on regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures, which supplements that Regulation, cf. Act No. 60/2021 on Actions against Market Abuse.

Further information please contact Kvika‘s investor relations,

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Datacubed Health Launches eClinical Platform App in China, Ensuring Full Compliance and Accessibility26.9.2023 15:03:00 CEST | Press release

Datacubed Health and AppInChina Forge Strategic Partnership to Launch eClinical Platform in China New York, New York, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Datacubed Health, a leading global provider of innovative solutions for patient engagement and data collection in clinical trials, is excited to announce the official launch of its eClinical platform app in China. This milestone achievement represents a significant step forward for Datacubed Health's commitment to expanding its presence in the Chinese market. As part of this strategic move, Datacubed Health has joined forces with AppInChina, a renowned leader in Android App Store publication, ensuring seamless deployment of the eClinical platform app in official Android stores across China and the Apple App Store. This partnership guarantees accessibility to a wide range of devices and ecosystems. Kyle Hogan, President of Datacubed Health, emphasized the importance of this collaboration: "Our partnership with AppInChina has been instru

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke26.9.2023 15:00:00 CEST | Press release

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin. The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutrukin in healthy volunteers. Sequential dose escalation was conducted using three cohorts of subjects, each receiving a single intravenous infusion of either placebo or Hutrukin, with eight subjects in each cohort. Hutrukin is a candidate drug being developed to reduce brain injury following ischemic stroke. Globally, one in four people over age 25 will experience a stroke—the leading cause of disability and second leading cause of death in the world. An ischemic stroke occurs when a blood clot ob

Inbjudan till webbsänd presentation och telefonkonferens i samband med SkiStar AB:s bokslutskommuniké för 2022/2326.9.2023 15:00:00 CEST | Pressemelding

SkiStar AB offentliggör sin bokslutskommuniké för perioden 1 september 2022 – 31 augusti 2023 tisdagen den 3 oktober 2023 klockan 07.00 CET. I samband med rapporten håller SkiStar en webbsänd presentation och telefonkonferens. Verkställande direktör Stefan Sjöstrand och ekonomi- och finansdirektör Martin Almgren presenterar och kommenterar rapporten. Efter presentationen kommer det att finnas möjlighet att ställa frågor både via telefon och e-mail i webbsändningen. Presentationen hålls på engelska. Tid för telefonkonferens och webbpresentation m.m. Tisdagen den 3 oktober 2023 klockan 10.00 CET. Webbsändning: För registrering och inringningsuppgifter till telefonkonferensen, följ länken ovan. Försäkra dig om att du är uppkopplad till telefonkonferensen genom att ringa in och registrera dig några minuter innan konferensen börjar. Presentationen och en inspelad version av webbsändningen kommer att finnas tillgänglig på samma webbplats efter sändni

Invitation to conference call with web presentation of SkiStar AB's Year-End Report för 2022/2326.9.2023 15:00:00 CEST | Press release

SkiStar AB will publish the Year-End Report for the period 1 September 2022 – 31 August 2023 on Tuesday 3 October 2023 at 07.00 a.m. CET. In connection with the report SkiStar will organize a conference call with web presentation. CEO Stefan Sjöstrand and CFO Martin Almgren will present and comment on the report. After the presentation there will be time for questions, both by phone and by e-mail in the web presentation. The presentation will be held in English. Time for conference call and web presentation Tuesday 3 October 2023 at 10.00 a.m. CET. Web cast: For registration and dial-in details, please follow the link above. Please make sure you are connected to the phone conference by calling in and registering a few minutes before the conference begins. The presentation and a recorded version of the web presentation will be available on the same webpage after the presentation. This information was submitted for publication, through the agency

Biogen Completes Acquisition of Reata Pharmaceuticals26.9.2023 14:59:54 CEST | Press release

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals’ lead asset, was approved for the treatment of Friedreich’s ataxia (FA), a rare neuromuscular disorder, in the United States earlier this year. FA is genetic, progressive, life-shortening, debilitating, and degenerative, affecting an estimated 5,000 diagnosed patients within the United States1. The commercial launch of SKYCLARYS® is underway in t